The association of angiogenic factors and chronic kidney disease

BMC Nephrology

Table 2 Angiogenesis-related factors according to chronic kidney disease status

	Age-gender-race-adjusted median (IQR)			Multivariable-adjusted median (IQR)^a
	CKD patients (n = 201)	Non-CKD controls (n = 201)	P	CKD patients (n = 201)	Non-CKD controls (n = 201)	P
VEGF-A, pg/mL	132.6 (90.4, 199.0)	112.5 (71.9, 166.8)	0.13	133.08 (90.39, 204.15)	114.17 (72.45, 170.32)	0.002
Angiopoeitin-1, pg/mL	3957.1 (2471.9, 6602.1)	4269.1 (2668.5, 6501.9)	0.34	3951.2 (2471.9, 6656.6)	4270.5 (2763.7, 6537.2)	0.70
Angiopoeitin-1/VEGF-A	25.80 (18.09, 47.90)	36.69 (25.71, 61.10)	< 0.001	25.87 (18.09, 47.90)	36.55 (25.71, 61.10)	< 0.001
VEGFR-1, ng/mL	148.0 (122.9, 167.9)	144.2 (123.7, 168.0)	0.92	147.81 (122.94, 168.79)	144.16 (123.74, 168.05)	0.25
VEGFR-2, ng/mL	26.1 (22.7, 29.9)	26.4 (23.1, 29.7)	0.79	26.20 (22.67, 29.92)	26.28 (23.10, 29.69)	0.31
Pentraxin-3, ng/mL	1.02 (0.79, 1.48)	0.86 (0.58, 1.17)	0.01	1.01 (0.79, 1.49)	0.89 (0.58, 1.18)	0.01

VEGF-A vascular endothelial growth factor A; VEGFR-1 = vascular endothelial growth factor receptor 1; VEGFR-2 = vascular endothelial growth factor receptor 2; CKD = chronic kidney disease; IQR = interquartile range
^aMultivariable adjusted model adjusted for age, race, gender, current cigarette smoking, weekly alcohol consumption, physical activity ≥twice/week, BMI, LDL-cholesterol, HDL-cholesterol, C-reactive protein, fasting plasma glucose, systolic BP, use of aspirin or lipid-lowering, antihypertensive, or antidiabetic medications, and history of CVD

ISSN: 1471-2369